Replies to post #450016 on ORIONS Money Stocks

[RLBLB]

$NSPR 8K

On June 10, 2020, InspireMD, Inc. (the “Company”) issued a press release announcing the publication of the results of its PARADIGM trial in the EuroIntervention journal. In that trial, 101 unselected consecutive real-life patients were treated with the Company’s CGuard™ MicroNET covered stent for carotid stenosis and were monitored for postprocedural neurologic events for a period of 12 months. The results displayed sustained protection against any such neurologic events. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.